Dilek BERKER, Serdar GULER, Mazhar Müslüm TUNA, Narin NASİROGLU IMGA, Derya KÖSEOĞLU, Berçem AYÇİÇEK, Mehtap NAVDAR BASARAN, Cagdas SENEL, Altug TUNCEL

Computed tomography and magnetic resonance imaging features for differentiating functioning from non-functioning adrenal lesions

Aim: It is not well known whether the radiological features of adenomas differ between functioning and non-functioning adrenal lesions (NFAL). The aim of this study was to evaluate the characteristic features of computed tomography (CT) and magnetic resonance imaging (MRI) characteristics among functioning and non-functioning adrenal lesions. Material and Methods: This retrospective study included 89 patients with functioning adrenal lesions and 148 patients with NFAL, whose CT or MRI findings were present. Group 1 included patients with functioning adrenal lesions and group 2 patients with NFAL. Results: In patients with functioning adrenal mass, adenoma size (p:0.001), unenhanced and early-enhanced Hounsfield units (HU) (p

PDF

___

1. Young WF Jr. Clinical Practice. The incidentally discovered adrenal mass. N Engl J Med 2007;356:601- 10.
2. Davenport C, Liew A, Doherty B, et al. The prevalence of adrenal incidentaloma in routine clinical practice. Endocr 2011;40:80-3.
3. Szász P, Kučera P, Čtvrtlík F, et al. Diagnostic Value of Unenhanced CT Attenuation and CT Histogram Analysis in Differential Diagnosis of Adrenal Tumors. Medicina (Kaunas) 2020; 56:597.
4. Zeiger MA, Thompson GB, Duh QY, et al. The American Association of Clinical Endocrinologists and American Association of Endocrine Surgeons medical guidelines for the management of adrenal incidentalomas. Endocr Pract 200915:1-20.
5. Mantero F, Terzolo M, Arnaldi G, et al. A survey on adrenal incidentaloma in Italy. Study group on adrenal tumors of the Italian Society of Endocrinology. J Clin Endocrinol Metab 2000;85:637-44.
6. Reincke M, Nieke J, Krestin GP, et al. Preclinical Cushing’s Syndrome in Adrenal Incidentalomas: Comparison with adrenal Cushing’s Syndrome. J Clin Endocrinol Metab 1992;75:826-32.
7. Blake MA, Kalra MK, Sweeney AT, et al. Distinguishing benign from malignant adrenal masses: multidetector row CT proto-col with 10-minute delay. Radiol 2006;238:578-85.
8. Jason DS, Oltmann SC. Evaluation of an Adrenal Incidentaloma. Surg Clin North Am 2019;99:721-9.
9. Cawood TJ, Hunt PJ, O’Shea D, et al. Recommended evaluation of adrenal incidentalomas is costly, has high false-positive rates and confers a risk of fatal cancer that is similar to the risk of the adrenal lesion becoming malignant; time for a rethink? Eur J Endocrinol 2009;161:513-27.
10. Cho YY, Suh S, Joung JY, et al. Clinical characteristics and follow-up of Korean patients with adrenal incidentalomas. Korean J Intern Med 2013;28:557-64.
11. Terzolo M, Stigliano A, Chiodini I, et al; Italian Association of Clinical Endocrinologists. AME position statement on adrenal incidentaloma. European Eur J Endocrinol 2011;164:851-70.
12. Grumbach MM, Biller BMK, Braunstein GD, et al. Management of the clinically inapparent adrenal mass (“Incidentaloma”). Ann Intern Med 2003;138:424–9.
13. Barzon L, Scaroni C, Sonino N, et al. Risk factors and long-term follow-up of adrenal incidentalomas. J Clin Endocrinol Metab 1999;84:520-6.
14. Hamrahian AH, Ioachimescu AG, Remer EM, et al. Clinical utility of noncontrast computed tomography attenuation value ( ounsfield units) to differentiate adrenal adenomas/hyperplasias from nonadenomas: Cleveland Clinic experience. J Clin Endocrinol Metab 2005;90:871-7.
15. Motta-Ramirez GA, Remer EM, Herts BB, et al. Comparison of CT findings in symptomatic and incidentally discovered pheochromocytomas. AJR Am J Roentgenol 2005;185:684-8.
16. Sane T, Schalin-Jantti C, Raade M. Is biochemical screening for pheochromocytoma in adrenal incidentalomas expressing low unenhanced attenuation on computed tomography necessary? J Clin Endocrinol Metab 2012;97:2077-83.
17. Reginelli A, Grezia GD, Izzo A, et al. Imaging of adrenal incidentaloma: Our experience. Int J Surg 2014;12:126-31.
18. Kim J, Bae KH, Choi YK, et al. Clinical Characteristics for 348 Patients with Adrenal Incidentaloma. Endocrinol Metab (Seoul) 2013;28:20-5.
19. Ctvrtlik F, Herman M, Student V, et al. Differential diagnosis of incidentally detected adrenal masses revealed on routine abdominal CT. Eur J Radiol 2009;69:243-52.
20. Kannan S, Remer EM, Hamrahian AH. Evaluation of patients with adrenal incidentalomas. Curr Opin Endocrinol Diabetes Obes 2013;20:161-9.
21. Chambre C, McMurray E, Baudry C, et al. The 10 Hounsfield units unenhanced computed tomography attenuation threshold does not apply to cortisol secreting adrenocortical adenomas. Eur J Endocrinol 2015;173:325-32.
22. Allen BC, Francis IR. Adrenal Imaging and Intervention. Radiol Clin North Am 2015;53:1021-35.
23. Patel J, Davenport MS, Cohan RH, et al. Can established CT attenuation and washout criteria for adrenal adenoma accurately exclude pheochromocytoma? AJR Am J Roentgenol 2013;201:122-7.
24. Rha SE, Byun JY, Jung SE, et al. Neurogenic tumors in the abdomen: tumor types and imaging characteristics. Radiographics 2003;23:29-43.
25. Francis IR, Korobkin M. Pheochromocytoma. Radiol Clin North Am 1996;34:1101-12.
26. Jacques AE, Sahdev A, Sandrasagara M, et al. Adrenal phaeochromocytoma: correlation of MRI appearances with histology and function. Eur Radiol 2008;18:2885- 92.
27. Maurea S, Mainenti PP, Romeo V, et al. Nuclear imaging to characterize adrenal tumors: Comparison with MRI. World J Radiol 2014;6:493-501.